Efferon LPS Hemoadsorption in in Patients With Thermal Burns
Extracorporeal Blood Purification Using Efferon LPS Hemoadsorption in Patients With Thermal Burns: Pilot Study
The aim of the study is to evaluate the safety and efficacy of multimodal (cytokine and lipopolysaccharide) hemoadsorption using the Efferon® LPS device to reduce the severity of clinical symptoms and to prevent the progression of multiple organ dysfunction or to arrest its development in patients with burn disease with an RFI score ≥71 and ≤181.
Patients will be randomized in two groups: control group receiving baseline therapy (including CRRT) and treatment group receiving baseline therapy and Efferon® LPS hemoadsorption in combination with CRRT.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Extensive burns are a severe form of trauma that, according to the World Health Organization, cause more than 180,000 deaths worldwide each year. Burn injury is not only a local tissue injury at the site of the damaging agent, but also triggers a complex systemic response to trauma. Severe burn injury induces a systemic inflammatory response associated with generalized microcirculatory disturbances in organs and tissues, cellular dystrophy and destruction, and the development of multiple organ dysfunction and failure. Burn trauma causes massive release of damage-associated molecular patterns (DAMPs) and pro-inflammatory cytokines, leading to systemic inflammatory response syndrome (SIRS), which may result in multiple organ failure and death. Mortality associated with multiple organ failure in burn patients reaches 81-87% among patients who develop this condition, and multiple organ failure remains the leading cause of death in burn patients. Among patients with a Sequential Organ Failure Assessment (SOFA) score ≥4 within the first 24 hours after injury, mortality reaches 81%.
The Efferon LPS hemoadsorption device was developed for use in sepsis, leveraging its ability to effectively target both primary and secondary inflammatory mediators. However, this approach also has significant potential in the treatment of burn injury, a condition characterized by a complex inflammatory response.
The goal of this study is to evaluate the safety and efficacy of multimodal (cytokine and lipopolysaccharide) hemoadsorption using the Efferon LPS device to reduce the severity of clinical manifestations and to prevent progression of multiple organ dysfunction, or mitigate it if already developed, in patients with burn disease and an RFI score ≥71 and ≤181.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Alexandr Shelehov-Kravchenko, PhD, MD
- Número de telefone: +79636564765
- E-mail: ais@efferon.ru
Locais de estudo
-
-
-
Moscow, Rússia, 129090
- N.V. Sklifosovsky Research Institute for Emergency Medicine
-
Contato:
- Vladimir Kulabukhov, PhD, MD
- Número de telefone: +79255068081
- E-mail: v.kulabukhov@gmail.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Thermal burns (flame, scald, or contact burns), including cases combined with inhalation injury
- Revised Frank Index (RFI) score ≥71 and ≤181
- Indication for extracorporeal therapy within the first 10 days after injury
- The patient's condition allows Efferon LPS therapy to be performed for at least 6 hours
Exclusion Criteria:
- Isolated thermal-inhalation injury
- Chemical, electrical, or solar burns of the skin
- Combined skin burns with frostbite and/or general hypothermia
- Combined trauma (electrical injury; traumatic brain injury other than concussion or mild cerebral contusion; skull, spinal, thoracic, pelvic, or femoral fractures) or acute pre-existing pathology prior to hospital admission (acute myocardial infarction, stroke, community-acquired pneumonia, or acute surgical conditions) that may influence the course and outcome of burn disease
- Cardiopulmonary resuscitation at the pre-hospital stage
- End-stage renal disease
- Acute pulmonary embolism confirmed by imaging
- Emergency surgical treatment
- Any other condition which, in the investigator's opinion, precludes inclusion of the patient in the study
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Sem intervenção: Baseline therapy
Patients receiving standard treatment for the treatment of thermal burns without the use of hemoadsorption methods, but who are prescribed continuous renal replacement therapy (CRRT) for renal and non-renal indications.
|
|
|
Experimental: Baseline therapy + Efferon LPS
Patients receiving standard therapy for the treatment of thermal burns, along with Efferon LPS hemoadsorption procedures in combination with continuous renal replacement therapy (CRRT).
|
Efferon LPS, a medical device, which is a single-use cartridge filled with a polymeric adsorbent that selectively adsorbs endotoxin via surface-immobilized ligand and excessive cytokines via its intrinsic porosity.hemoadsorption
procedures, each lasting 6-12 hours, with an interval of at least 24 hours between hemoadsorption sessions (from the start of the first procedure).
The procedures are performed in combination with continuous renal replacement therapy (CRRT).
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Need for vasopressor support
Prazo: 1-28 days
|
Need for vasopressors according to the Vasoactive inotropic score (VIS 2020) heart rate scale.
VIS is calculated as a weighted sum of all administered vasoactive inotropic agents.
|
1-28 days
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Horowitz oxygenation index
Prazo: 1-28 days
|
Value of oxygenation index (Pa02 / Fi02 (Pa).
|
1-28 days
|
|
Renal replacement therapy (RRT) free days
Prazo: 1-28 days
|
RRT-free days = 0 if the subject dies within 28 days of starting renal replacement therapy. RRT-free days = 28 - x if RRT is successfully discontinued x days after initiation. RRT-free days = 0 if the subject requires RRT for more than 28 days. |
1-28 days
|
|
28 and 60 days mortality
Prazo: 1-60 days
|
Mortality rate
|
1-60 days
|
|
Length of stay in the intensive care unit
Prazo: 1-60 days
|
Time (number of days) from study enrollment to transfer from the intensive care unit within 60 days
|
1-60 days
|
|
Duration of hospitalization
Prazo: 1-60 days
|
Time (number of days) from study enrollment to discharge from the hospital
|
1-60 days
|
|
Frequency of septic complications
Prazo: 1-28 days
|
Percentage of patients with septic complications
|
1-28 days
|
|
Frequency of surgical interventions
Prazo: 1-28 days
|
Percentage of patients requiring surgery
|
1-28 days
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Vladimir Kulabukhov, PhD, MD, N.V. Sklifosovsky Research Institute for Emergency Medicine
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- efferon-lps-2026-01
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .